Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response
Portfolio Pulse from Vandana Singh
Lineage Cell Therapeutics Inc and Cancer Research UK have revealed results from a clinical study of VAC2 in advanced non-small cell lung cancer. The study showed that VAC2 was well-tolerated, with no unexpected serious adverse events. Five of eight patients treated had a best response of immune-related stable disease, and three demonstrated immune-related progressive disease. Three of eight treated patients reached the 2-year survival endpoint. LCTX shares are down 0.70% at $1.41.
July 24, 2023 | 5:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lineage Cell Therapeutics' clinical study of VAC2 showed promising results, but the company's shares are down 0.70%.
The clinical study results are promising, indicating that VAC2 is well-tolerated and can lead to immune-related stable disease in some patients. However, despite these positive results, the company's shares are down, which could be due to market factors or investor sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100